<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 7, 2020 (HealthDay News) — For patients with type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors do not increase the risk for below-knee amputation compared with dipeptidyl peptidase 4 (DPP-4) inhibitors, according to a study published online Aug. 5 in Diabetes Care<\/i>.<\/p>\n
Oriana Hoi Yun Yu, M.D., from the Jewish General Hospital in Montreal, and colleagues conducted a multicenter observational study using administrative health care databases to compare the risk for below-knee amputation with SGLT2 inhibitors versus DPP-4 inhibitors among patients with type 2 diabetes. Data were included for 207,817 incident SGTL2 inhibitor users matched to 207,817 DPP-4 inhibitor users.<\/p>\n
The researchers found amputation rates of 1.3 and 1.5 per 1,000 person-years among SGLT2 inhibitor users and DPP-4 inhibitor users, respectively, during a mean exposed follow-up time of 11 months. For below-knee amputations, the adjusted hazard ratio was 0.88 (95 percent confidence interval, 0.71 to 1.09) in association with SGLT2 inhibitor use versus DPP-4 inhibitor use. In stratified analyses by specific SGLT2 inhibitor molecule, similar results were obtained.<\/p>\n
“Future studies will be needed to further address whether SGLT2 inhibitor use increases the risk of incident below-knee amputation over the longer term,” the authors write.<\/p>\n
One author disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n